Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9

Area of Science:

• Virology
• Molecular Biology
• Gene Editing

Background:

• Progressive Multifocal Leukoencephalopathy (PML) is a severe neurological disease caused by JC polyomavirus (JCPyV) infection of oligodendrocytes.
• There is currently no effective antiviral therapy for JCPyV infection, highlighting a critical unmet medical need.

Purpose of the Study:

• To investigate the potential of the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) system as a therapeutic strategy against JCPyV.
• To evaluate the efficacy of CRISPR/Cas9 in restricting the JCPyV life cycle in vitro.

Main Methods:

• CRISPR/Cas9 system was designed to target specific regions of the JCPyV genome, including the noncoding control region and the late gene open reading frame.
• The delivery of Cas9 and JCPyV-specific single-guide RNA was performed in cultured cells before or after JCPyV infection.

Main Results:

• Significant inhibition of JCPyV replication was observed in cells treated with the CRISPR/Cas9 system.
• Reduced expression of viral proteins was detected, indicating effective disruption of the JCPyV life cycle.
• The CRISPR/Cas9 system demonstrated efficacy in restricting viral activity when delivered both pre- and post-infection.

Conclusions:

• The CRISPR/Cas9 system is a viable tool for restricting the JCPyV life cycle and holds potential for developing novel antiviral therapies for PML.
• Targeting critical regions of the JCPyV genome with CRISPR/Cas9 offers a sequence-specific approach to combatting viral replication.